Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models

▸ TREATMENT

Fruquintinib, an oral inhibitor of all three vascular endothelial growth factor receptors that has been approved for chemorefractory CRC, showed combined antitumor activity with TAS-102 in xenograft models. (BMC Cancer)